Georgia's Online Cancer Information Center


back

Bladder Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Bladder Cancer
Cancer Type = Bladder Cancer
NCI ID Cancer Type Trial Name
There are currently 14 active Bladder Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Beta-only IL-2 ImmunoTherapY Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
2.
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Cancer Type
Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Unknown Primary
NCT ID
NCT06120075
Protocol IDs
ARC-27
NCI-2024-03901
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
3.
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT04879329
Protocol IDs
RC48G001
NCI-2022-03375
2022-500030-28
2022-500030-28-01
C5731002
KEYNOTE-D78
MK-3475-D78
RC48 G001
4.
Blue Light Cystoscopy With Cysview® Registry
Cancer Type
Bladder Cancer
NCT ID
NCT02660645
Protocol IDs
BLCCR-001
NCI-2018-00299
5.
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04878029
Protocol IDs
WINSHIP5259-21
NCI-2021-01365
STUDY00002329
6.
NCORP Trial
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCT ID
NCT05366881
Protocol IDs
Adela-EDMRD-001
NCI-2022-04272
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
7.
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Cancer Type
Bladder Cancer
NCT ID
NCT03711032
Protocol IDs
3475-676
NCI-2019-00740
2018-001967-22
MK-3475-676
Treatment Sites (2)
Advanced Urology - Alpharetta
Roswell
Emory University Hospital - Atlanta
Atlanta
8.
Enfortumab Vedotin plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Cancer Type
Bladder Cancer
NCT ID
NCT05756569
Protocol IDs
WINSHIP5742-22
NCI-2023-00104
STUDY00005143
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
9.
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04752722
Protocol IDs
EG-70-101
NCI-2021-12422
10.
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04452591
Protocol IDs
CG3002S
NCI-2021-01691
11.
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT06632951
Protocol IDs
M25-204
NCI-2024-10299
2024-515506-11-00
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
12.
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type
Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer
NCT ID
NCT03866382
Protocol IDs
A031702
A031702
NCI-2019-01266
Treatment Sites (4)
Emory Johns Creek Hospital
Johns Creek
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
13.
NCORP Trial
Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy after Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT05987241
Protocol IDs
A032103
A032103
NCI-2023-05980
Treatment Sites (6)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Emory Johns Creek Hospital
Johns Creek
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
14.
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT06510374
Protocol IDs
000423
NCI-2025-01046
U1111-1284-0685
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Georgia CORE bridges the gap between groundbreaking research, educational outreach, and effective advocacy to transform the landscape of cancer care for all Georgians.